Tysabri and PML: What the Latest Research Shows About Risk Management
Latest update (2026-07)
- Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Literacy to Specific Risk Awareness
If you or a loved one is taking Tysabri, you may have heard about the risk of progressive multifocal leukoencephalopathy (PML) and wondered how to weigh treatment benefits against potential harm. Decades of pharmacovigilance and clinical research have established PML as a rare but serious complication of certain immunosuppressive therapies, including natalizumab. This page reviews recent research updates on risk stratification, monitoring protocols, and what these findings mean for informed care discussions.
Understanding Tysabri and Its Link to PML
Tysabri (natalizumab) is a biologic therapy approved for the treatment of multiple sclerosis and Crohn's disease. Its prescribing information carries a boxed warning stating that Tysabri increases the risk of progressive multifocal leukoencephalopathy (PML), an opportunistic viral infection of the brain caused by the JC virus (JCV) that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). PML typically occurs only in patients who are immunocompromised, and its clinical presentation includes progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis relies on brain MRI and detection of JCV DNA in cerebrospinal fluid. The mechanistic pathway linking Tysabri to PML involves its pharmacological action. Tysabri is a monoclonal antibody that binds to alpha-4 integrins on the surface of immune cells, preventing their migration across the blood-brain barrier into the central nervous system. This reduces inflammation in multiple sclerosis but also impairs immune surveillance against JCV, allowing the virus to reactivate and cause lytic infection of oligodendrocytes, leading to demyelination and the characteristic lesions of PML. Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The boxed warning emphasizes that these factors should be considered in the context of expected benefit when initiating and continuing treatment. Healthcare professionals are instructed to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first such sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Legal Scrutiny and Settlement Context
The adequacy of warnings regarding Tysabri and PML has been a subject of legal scrutiny. The boxed warning explicitly states that Tysabri increases the risk of PML and that the infection usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). However, some patients and their families have alleged that the warnings were insufficient to convey the magnitude of risk or that they were not adequately communicated. The TOUCH Prescribing Program, a restricted distribution program, requires patients to read a Medication Guide, understand the risks, and sign an enrollment form (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Healthcare professionals must evaluate patients at specified intervals—three months after the first infusion, six months after the first infusion, every six months thereafter, and for at least six months after discontinuing Tysabri—and determine every six months whether treatment should continue (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these measures, PML cases have occurred, leading to settlements and litigation. For affected patients in California, settlement-related considerations involve the statute of limitations, which is the time limit for filing a lawsuit. In California, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date of injury or from when the injury was discovered or should have been discovered through reasonable diligence. For PML, the timeline between exposure to Tysabri and documented harm can be variable. PML may develop months to years after starting Tysabri, and symptoms can be subtle initially, delaying diagnosis. The boxed warning notes that risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency period complicates the determination of when the statute of limitations begins to run. Courts may apply the "discovery rule," which starts the clock when the plaintiff knew or should have known of the injury and its cause. Patients who developed PML after Tysabri treatment should consult legal counsel promptly to assess their individual circumstances, as delays could bar recovery. Settlement amounts for Tysabri-related PML cases have varied based on factors such as severity of disability, medical expenses, lost income, and pain and suffering. The boxed warning's acknowledgment that PML usually leads to death or severe disability underscores the catastrophic nature of the injury (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who survive often require lifelong care, which can be factored into settlement negotiations. The TOUCH program's monitoring requirements also create documentation that may be relevant in litigation, as deviations from recommended monitoring could support claims of inadequate warning or negligence.
Statute of Limitations for Tysabri Claims in California
In California, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date of injury or from when the injury was discovered or should have been discovered through reasonable diligence. For PML, the timeline between exposure to Tysabri and documented harm can be variable. PML may develop months to years after starting Tysabri, and symptoms can be subtle initially, delaying diagnosis. The boxed warning notes that risk increases with longer treatment duration, especially beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This latency period complicates the determination of when the statute of limitations begins to run. Courts may apply the "discovery rule," which starts the clock when the plaintiff knew or should have known of the injury and its cause. Patients who developed PML after Tysabri treatment should consult legal counsel promptly to assess their individual circumstances, as delays could bar recovery.
Evidence Summary and Risk Context
In summary, the evidence establishes that Tysabri carries a known risk of PML, with specific risk factors and a requirement for monitoring. For California patients, the statute of limitations is a critical consideration, and the timeline between exposure and harm may affect when the clock starts. Settlement considerations depend on the severity of harm and the adequacy of warnings provided. Patients should seek legal advice to understand their rights and options. References https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Tysabri-related PML claims in California?
In California, the statute of limitations for personal injury claims, including those related to pharmaceutical products, is generally two years from the date of injury or from when the injury was discovered or should have been discovered through reasonable diligence. For PML, the timeline between exposure to Tysabri and documented harm can be variable, and courts may apply the discovery rule. Patients should consult legal counsel promptly to assess their individual circumstances.
What are the risk factors for developing PML while taking Tysabri?
Three established risk factors for PML in Tysabri-treated patients are the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
- Texas Tysabri Progressive Multifocal Leukoencephalopathy injury lawyer
- Georgia Tysabri Progressive Multifocal Leukoencephalopathy injury lawyer
- Does Tysabri cause Progressive Multifocal Leukoencephalopathy
- Statute of limitations for Tysabri in Arizona
- Statute of limitations for Tysabri in Washington
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.